These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 22017376)
1. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells. Iwata S; Saito T; Ito Y; Kamakura M; Gotoh K; Kawada J; Nishiyama Y; Kimura H Cancer Sci; 2012 Feb; 103(2):375-81. PubMed ID: 22017376 [TBL] [Abstract][Full Text] [Related]
2. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection. Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988 [TBL] [Abstract][Full Text] [Related]
3. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Kawada J; Ito Y; Iwata S; Suzuki M; Kawano Y; Kanazawa T; Siddiquey MN; Kimura H Clin Cancer Res; 2014 Nov; 20(21):5412-22. PubMed ID: 25208880 [TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma. Siddiquey MN; Nakagawa H; Iwata S; Kanazawa T; Suzuki M; Imadome K; Fujiwara S; Goshima F; Murata T; Kimura H Cancer Sci; 2014 Jun; 105(6):713-22. PubMed ID: 24712440 [TBL] [Abstract][Full Text] [Related]
5. Coexpression of CD40 and CD40 ligand in Epstein-Barr virus-infected T and NK cells and their role in cell survival. Imadome K; Shimizu N; Arai A; Miura O; Watanabe K; Nakamura H; Nonoyama S; Yamamoto K; Fujiwara S J Infect Dis; 2005 Oct; 192(8):1340-8. PubMed ID: 16170750 [TBL] [Abstract][Full Text] [Related]
11. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Feng WH; Kenney SC Cancer Res; 2006 Sep; 66(17):8762-9. PubMed ID: 16951192 [TBL] [Abstract][Full Text] [Related]
12. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034 [TBL] [Abstract][Full Text] [Related]
13. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Ando S; Kawada JI; Watanabe T; Suzuki M; Sato Y; Torii Y; Asai M; Goshima F; Murata T; Shimizu N; Ito Y; Kimura H Oncotarget; 2016 Nov; 7(47):76793-76805. PubMed ID: 27732937 [TBL] [Abstract][Full Text] [Related]
14. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Ohshima K; Kimura H; Yoshino T; Kim CW; Ko YH; Lee SS; Peh SC; Chan JK; Pathol Int; 2008 Apr; 58(4):209-17. PubMed ID: 18324913 [TBL] [Abstract][Full Text] [Related]
15. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death. Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Fukunaga S; Futani H; Okamura H; Terada N Int J Oncol; 2012 Jul; 41(1):83-91. PubMed ID: 22576685 [TBL] [Abstract][Full Text] [Related]
16. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. Hui KF; Chiang AK Int J Cancer; 2010 May; 126(10):2479-89. PubMed ID: 19816947 [TBL] [Abstract][Full Text] [Related]
17. Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. Jones K; Nourse J; Corbett G; Gandhi MK Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e169-74. PubMed ID: 19196381 [TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884 [TBL] [Abstract][Full Text] [Related]
19. NK-cell repertoire is feasible for diagnosing Epstein-Barr virus-infected NK-cell lymphoproliferative disease and evaluating the treatment effect. Sawada A; Sato E; Koyama M; Higuchi B; Kusuki S; Kim JY; Takeshita Y; Sakata A; Sakata N; Okamura T; Yasui M; Inoue M; Kawa K Am J Hematol; 2006 Aug; 81(8):576-81. PubMed ID: 16823820 [TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]